ArticleCancers2022

Phase 1/2 Trial of CLAG-M with Dose-Escalated Mitoxantrone in Combination with Fractionated-Dose Gemtuzumab Ozogamicin for Newly Diagnosed Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms.

Colin D Godwin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.